Follows an index or a price, bought and sold like a share
Past returns do not tell you future returns. Tap a dotted word to see what it means.
Against Nifty Pharma TRI
| Return | This fund | Similar funds | Rank | |
|---|---|---|---|---|
| 1 month | — | — | — | — |
| 3 months | — | — | — | — |
| 6 months | — | — | — | — |
| 1 year | — | +22.0% | -1.9% | — |
| 3 years, a year | — | +23.1% | +11.6% | — |
| 5 years, a year | — | +15.2% | +8.8% | — |
| Since launch, a year | — | — | — | — |
Shown once the fund has a full calendar year of prices.
What an investment in this fund would be worth today
How bumpy it has been, and how far it has fallen
How widely the price swung (volatility). Lower is steadier.
The deepest drop from a high before it recovered (drawdown).
Return above cash for each unit of bumpiness. Higher is better.
Like Sharpe, counting only the falls.
52-week range: ₹25.76 (26 Oct 2026) to ₹27.20 (3 Nov 2026). Now at its high.
Its yearly expense ratio, and how much money it manages
Of the 0.25%, 0.21% is the fund house's fee and 0.04% is trading costs and taxes, which move from month to month with the fund's buying and selling.
The expense ratio is taken out of the fund every day, so the NAV and every return on this page are already after it. How the expense ratio works
Entry Load nil. Exit Load: There will be no exit load for units sold through the secondary market on the stock exchanges where the Scheme will be listed. Currently, the Scheme is proposed to be listed on BSE and NSE. Investors shall note that the brokerage on sales of the units of the scheme on the stock exchanges shall be borne by the investors. However, during the process of creation/ redemption there may be transaction costs & /or other incidental expenses(forming part of the Cash Compon
The objective of the investment scheme is to provide returns before expenses that closely correspond to the total return of the underlying index, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.
The largest funds with the same mandate
ICICI Prudential Nifty Pharma ETF ICICI Prudential | — | — | — | 0.25% | ₹6 cr |
| -6.7% | +8.5% | +7.1% | 0.05% | ₹2.11 lakh cr | |
| -7.6% | +7.2% | +6.4% | 0.05% | ₹1.22 lakh cr | |
| -6.6% | +8.6% | +7.1% | 0.00% | ₹72,911 cr | |
Nippon India ETF Nifty 50 BeES Nippon India | -6.6% | +8.6% | +7.2% | 0.05% | ₹69,187 cr |
| -7.5% | +7.2% | +6.4% | 0.00% | ₹57,651 cr | |
ICICI Prudential Nifty 50 ETF ICICI Prudential | -6.6% | +8.6% | +7.2% | 0.03% | ₹45,378 cr |
ICICI Prudential BSE Sensex ETF ICICI Prudential | -7.6% | +7.3% | +6.4% | 0.03% | ₹33,941 cr |
Nippon India ETF BSE Sensex Nippon India | -7.6% | +7.3% | +6.4% | 0.04% | ₹29,812 cr |
Nippon India ETF Nifty Next 50 Junior BeES Nippon India | -0.4% | +16.6% | +10.9% | 0.26% | ₹8,695 cr |
Nippon India ETF Nifty Bank BeES Nippon India | -4.0% | +9.2% | +7.7% | 0.21% | ₹8,049 cr |
The NAV of the fund was ₹27.20 on 3 Nov 2026.
Over the last three years its NAV fell as much as -0.1% from a high before recovering; over the last year, -0.1%.
0.25% a year, against a typical 0.25% in its category. It is taken out of the fund daily, so the NAV and returns are after it.
It manages ₹6.5 cr as of 2 Nov 2026.
Entry Load nil. Exit Load: There will be no exit load for units sold through the secondary market on the stock exchanges where the Scheme will be listed. Currently, the Scheme is proposed to be listed on BSE and NSE. Investors shall note that the brokerage on sales of the units of the scheme on the stock exchanges shall be borne by the investors. However, during the process of creation/ redemption there may be transaction costs & /or other incidental expenses(forming part of the Cash Compon
₹1,000 to start.
Its riskometer level is Very High, on SEBI's six-step scale from Low to Very High. Its NAV's volatility over the last year was 11.6%.
Nifty Pharma TRI.
On 12 Oct 2026.